Pembrolizumab (Keytruda) is an immunotherapy used to treat melanoma. It works by blocking a protein called PD-1, which cancer cells use to hide from the immune system. By blocking this "off switch," it allows the body's T cells to recognize and attack melanoma cells.
There are now two ways it can be given:
- IV infusion Show Full Answer
Pembrolizumab (Keytruda) is an immunotherapy used to treat melanoma. It works by blocking a protein called PD-1, which cancer cells use to hide from the immune system. By blocking this "off switch," it allows the body's T cells to recognize and attack melanoma cells.
There are now two ways it can be given:
- IV infusion (Keytruda) — delivered through a vein over about 30 minutes
- Subcutaneous injection (Keytruda Qlex) — a quick 1–2 minute under-the-skin injection in the thigh or abdomen, given by a healthcare provider Both versions have been shown to work equally well. The injectable version is approved for:
- Unresectable or metastatic melanoma in adults
- Adjuvant (post-surgery) treatment for adults and adolescents aged 12+ with stage 2B, 2C, or 3 melanoma to help prevent recurrence Common side effects to be aware of include:
- Fatigue
- Muscle or bone pain
- Rash or itching
- Diarrhea or constipation
- Nausea or stomach pain
- Fever or cough
- Decreased appetite
- Underactive thyroid
There are also rarer but more serious risks, including inflammation of the lungs, bowel, liver, or kidneys, as well as severe skin reactions. These happen when the immune system mistakenly attacks healthy organs, so it's important to report any new or unusual symptoms to a healthcare provider promptly. The newer injectable format (Keytruda Qlex) is a convenient option since it doesn't require a port or a lengthy infusion center visit. That said, every situation is different, so discussing which format fits best with a healthcare provider is the right move.
May 25
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
